Editors' ChoiceFOCIS HIGHLIGHTS

Slamming the brakes on lupus with CAR T cells

See allHide authors and affiliations

Science Immunology  05 Apr 2019:
Vol. 4, Issue 34, eaax3916
DOI: 10.1126/sciimmunol.aax3916

Abstract

Sustained depletion of B cells with CAR T cells induces disease remission in lupus-prone mice.

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by periodic inflammatory flares in multiple organ systems and the formation of autoantibodies. The B cell–depleting anti-CD20 antibody Rituximab failed to improve lupus in two clinical trials, but these patients may have had incomplete or transient B cell depletion. To improve B cell depletion, Kansal et al. engineered CD19-targeted chimeric antigen receptor (CAR) CD8+ T cells and used them to treat lupus-prone mice. A single dose of CAR T cells depleted CD19+ B cells for up to a year, abolished the production of autoantigens, reversed tissue injury, and extended lifespan in two different strains of lupus-prone mice. CAR T cells were long-lived in the circulation and appeared to adopt a central memory T cell phenotype. T cells from the spleens of CAR-treated mice were able to transfer B cell depletion and disease remission to naïve autoimmune mice, confirming that T cells were responsible for disease control. Circulating immunoglobulin G (IgG) and IgM antibody levels remained normal in CAR T treated MRLfas/fas (MRL-lpr) lupus-prone mice, likely because long-lived plasma cells in the bone marrow and some splenic B cells were spared. CAR T cells directly kill B cells, whereas monoclonal antibodies rely on antibody-dependent cellular cytotoxicity for B cell depletion, an immune mechanism that is blunted in patients with SLE. These studies highlight a novel method of inducing sustained B cell depletion that overcomes current limitations in monoclonal antibody therapy and may hold promise for the treatment of patients with severe SLE.

Highlighted Article

View Abstract

Stay Connected to Science Immunology

Navigate This Article